Invesco Health Care Fund C (GTHCX)
17.46
+0.16
(+0.92%)
USD |
Jul 09 2025
Key Stats
Customize
| Net Expense Ratio | Total Assets Under Management | Weighted Average Dividend Yield | Turnover Ratio (Generic) |
|---|---|---|---|
| 1.80% | 1.179B | 0.83% | 56.00% |
| 1 Year Fund Level Flows | 1 Year Total Returns (Daily) | Annualized Total Returns Since Inception (Daily) | Max Drawdown (Since Inception) |
| -122.82M | -6.14% | Upgrade | Upgrade |
Basic Info
| Investment Strategy | |
| The Fund seeks long-term growth of capital. The Fund invests, under normal circumstances, at least 80% of its net assets in securities of issuers engaged primarily in health care-related industries, and in derivatives and other instruments that have economic characteristics similar to such securities. |
| General | |
| Security Type | Mutual Fund |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Global Peer Group | Equity Sector Healthcare |
| Peer Group | Global Health/Biotechnology Funds |
| Global Macro | Equity Industry Sector |
| US Macro | World Sector Equity Funds |
| YCharts Categorization | -- |
| YCharts Benchmark | -- |
| Prospectus Objective | Global Health/Biotechnology Funds |
| Fund Owner Firm Name | Invesco |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
Net Fund Flows Versus Peer Group
1 Month
% Rank:
64
-518.97M
Peer Group Low
97.96M
Peer Group High
1 Year
% Rank:
66
-122.82M
-6.147B
Peer Group Low
34.08M
Peer Group High
3 Months
% Rank:
57
-1.640B
Peer Group Low
5.743M
Peer Group High
3 Years
% Rank:
78
-13.06B
Peer Group Low
152.40M
Peer Group High
6 Months
% Rank:
58
-3.441B
Peer Group Low
68.66M
Peer Group High
5 Years
% Rank:
78
-20.76B
Peer Group Low
723.55M
Peer Group High
YTD
% Rank:
58
-3.441B
Peer Group Low
68.66M
Peer Group High
10 Years
% Rank:
70
-39.00B
Peer Group Low
570.87M
Peer Group High
Date Unavailable
Risk
Performance Versus Peer Group
Annual Total Returns Versus Peers
As of July 10, 2025.
Asset Allocation
As of May 31, 2025.
| Type | % Net |
|---|---|
| Cash | 3.42% |
| Stock | 95.37% |
| Bond | 1.22% |
| Convertible | 0.00% |
| Preferred | 0.00% |
| Other | 0.00% |
Top 10 Holdings
| Name | % Weight | Price | % Change |
|---|---|---|---|
| Boston Scientific Corp | 9.75% | 103.81 | 0.83% |
| Eli Lilly and Co | 8.15% | 789.08 | 0.27% |
| Stryker Corp | 4.90% | 394.75 | 0.69% |
| Cencora Inc | 4.09% | 297.26 | -0.97% |
| AbbVie Inc | 4.09% | 194.95 | 2.27% |
| Abbott Laboratories | 3.74% | 133.59 | 0.28% |
| Vertex Pharmaceuticals Inc | 3.60% | 479.73 | 0.16% |
| Intuitive Surgical Inc | 3.42% | 526.05 | -0.39% |
| Invesco Treasury Portfolio Institutional | 2.80% | 1.00 | 0.00% |
| UnitedHealth Group Inc | 2.48% | 299.29 | -1.20% |
Fees & Availability
| Fees | |
| Actual 12B-1 Fee | 1.00% |
| Actual Management Fee | 0.63% |
| Administration Fee | -- |
| Maximum Front Load | -- |
| Maximum Deferred Load | 1.00% |
| Maximum Redemption Fee | 0.00% |
| General Availability | |
| Available for Insurance Product | -- |
| Available for RRSP | -- |
| Purchase Details | |
| Open to New Investors |
|
| Minimum Initial Investment | 1000.00 None |
| Minimum Subsequent Investment | 50.00 None |
Basic Info
| Investment Strategy | |
| The Fund seeks long-term growth of capital. The Fund invests, under normal circumstances, at least 80% of its net assets in securities of issuers engaged primarily in health care-related industries, and in derivatives and other instruments that have economic characteristics similar to such securities. |
| General | |
| Security Type | Mutual Fund |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Global Peer Group | Equity Sector Healthcare |
| Peer Group | Global Health/Biotechnology Funds |
| Global Macro | Equity Industry Sector |
| US Macro | World Sector Equity Funds |
| YCharts Categorization | -- |
| YCharts Benchmark | -- |
| Prospectus Objective | Global Health/Biotechnology Funds |
| Fund Owner Firm Name | Invesco |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
Fundamentals
| General | |
| Distribution Yield | -- |
| Dividend Yield TTM (7-8-25) | 0.00% |
| 30-Day SEC Yield | -- |
| 7-Day SEC Yield | -- |
| Stock | |
| Weighted Average PE Ratio | 43.02 |
| Weighted Average Price to Sales Ratio | 8.154 |
| Weighted Average Price to Book Ratio | 10.88 |
| Weighted Median ROE | 10.67% |
| Weighted Median ROA | 4.11% |
| ROI (TTM) | 2.76% |
| Return on Investment (TTM) | 2.76% |
| Earning Yield | 0.0311 |
| LT Debt / Shareholders Equity | 3.108 |
As of May 31, 2025
Growth Metrics
| EPS Growth (1Y) | 26.10% |
| EPS Growth (3Y) | 16.19% |
| EPS Growth (5Y) | 15.64% |
| Sales Growth (1Y) | 19.25% |
| Sales Growth (3Y) | 15.00% |
| Sales Growth (5Y) | 17.12% |
| Sales per Share Growth (1Y) | 41.26% |
| Sales per Share Growth (3Y) | 12.81% |
| Operating Cash Flow - Growth Ratge (3Y) | 9.30% |
As of May 31, 2025
Fund Details
Top Portfolio Holders
| Name | % Weight |
|---|---|
| Portfolio A | 5.00% |
| Portfolio B | 3.50% |
| Portfolio C | 2.25% |
Excel Add-In Codes
| Name: =YCI("M:GTHCX", "name") |
| Broad Asset Class: =YCI("M:GTHCX", "broad_asset_class") |
| Broad Category: =YCI("M:GTHCX", "broad_category_group") |
| Prospectus Objective: =YCI("M:GTHCX", "prospectus_objective") |
| To find the codes for any of our securities and financial metrics, see our Complete Excel Reference. |